Auryxia is a drug owned by Keryx Biopharmaceuticals Inc. It is protected by 15 US drug patents filed from 2014 to 2019. Out of these, 3 drug patents are active and 12 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 21, 2030. Details of Auryxia's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Auryxia's patents.

Latest Legal Activities on Auryxia's Patents

Given below is the list of recent legal activities going on the following patents of Auryxia.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 12th Year, Large Entity	17 Apr, 2024	US8299298
Payment of Maintenance Fee, 8th Year, Large Entity	27 Dec, 2023	US9387191
Payment of Maintenance Fee, 12th Year, Large Entity	28 Jun, 2023	US8093423
Payment of Maintenance Fee, 4th Year, Large Entity	11 Nov, 2022	US10300039
Payment of Maintenance Fee, 8th Year, Large Entity	09 Nov, 2022	US9050316
Entity Status Set To Undiscounted (Initial Default Setting or Status Change)	09 Nov, 2022	US10300039
Payment of Maintenance Fee, 8th Year, Large Entity	09 Mar, 2022	US8846976
Payment of Maintenance Fee, 12th Year, Large Entity	13 Jan, 2022	US7767851
Payment of Maintenance Fee, 8th Year, Large Entity	11 Nov, 2021	US8754258
Payment of Maintenance Fee, 8th Year, Large Entity	11 Nov, 2021	US8754257

FDA has granted several exclusivities to Auryxia. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Auryxia, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Auryxia.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Auryxia's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Auryxia's generic, the next section provides detailed information on ongoing and past EP oppositions related to Auryxia patents.

Auryxia's Oppositions Filed in EPO

Auryxia has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 25, 2015, by Hexal Ag. This opposition was filed on patent number EP06813544A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP07717051A	Dec, 2016	Hexal AG	Opposition rejected
EP06813544A	Nov, 2015	Hexal AG	Revoked

US patents provide insights into the exclusivity only within the United States, but Auryxia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Auryxia's family patents as well as insights into ongoing legal events on those patents.

Auryxia's Family Patents

Auryxia has patent protection in a total of 23 countries. It's US patent count contributes only to 35.8% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Auryxia.

Full family tree

Generic Launch

About Auryxia

Auryxia is a drug owned by Keryx Biopharmaceuticals Inc. It is used for lowering and managing serum phosphorus levels. Auryxia uses Ferric Citrate as an active ingredient. Auryxia was launched by Keryx Biopharms in 2014.